Biogen Acquires Apellis for $5.6 Billion Cash Deal

has finalized an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, supplemented by contingent value rights linked to global net sales of Syfovre, as reported by MT Newswires on March 31, 2026. This strategic acquisition significantly expands Biogen's therapeutic portfolio, particularly enhancing its presence in the ophthalmology market with Syfovre, a key asset from Apellis.

The transaction underscores Biogen's commitment to growth through external innovation and portfolio diversification. The deal structure, including contingent value rights, aligns the interests of both companies by tying additional payments to the future commercial success of Syfovre.

This move positions Biogen to leverage its extensive commercial infrastructure and research capabilities to maximize the market penetration and long-term value of Apellis's assets. The acquisition is a definitive step for Biogen in strengthening its competitive standing within the highly dynamic pharmaceutical industry.